OTCMKTS:CPHRF Cipher Pharmaceuticals (CPHRF) Stock Price, News & Analysis $11.68 -0.02 (-0.17%) As of 03:44 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesBuy This Stock About Cipher Pharmaceuticals Stock (OTCMKTS:CPHRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cipher Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.68▼$11.7450-Day Range$11.30▼$12.7352-Week Range$8.64▼$15.00Volume1,053 shsAverage Volume4,809 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company that develops, acquires and commercializes prescription products in respiratory and dermatology markets. Founded in 2004 and headquartered in Vancouver, British Columbia, the company focuses on in-licensing established therapies and launching them under its own commercial infrastructure in North America. In the respiratory segment, Cipher markets generic inhalation therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). These include dry-powder inhalers (DPIs) and metered-dose inhalers (MDIs) that offer patients lower-cost alternatives to branded drugs. In dermatology, the company has brought to market treatments addressing acne, fungal infections of the nails and other skin disorders, often through licensing agreements with innovator companies. Cipher operates primarily in Canada and the United States. Its business model emphasizes strategic partnerships and licensing arrangements, enabling the company to secure exclusive Canadian rights to new products while collaborating with third-party partners for U.S. commercialization. This approach allows Cipher to leverage established regulatory approvals and focus resources on market access, sales and marketing. Looking ahead, Cipher continues to expand its product pipeline through in-licensing and development of both generic and branded prescription drugs. The company is advancing new formulations in respiratory care and exploring additional dermatology assets, aiming to build a diversified specialty pharmaceutical portfolio that delivers growth through product launches and ongoing royalty streams.AI Generated. May Contain Errors. Read More Receive CPHRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CPHRF Stock News HeadlinesCipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?July 14, 2026 | americanbankingnews.comCipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®July 6, 2026 | finance.yahoo.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.July 22 at 1:00 AM | Porter & Company (Ad)CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)April 7, 2026 | businesswire.comCipher Pharmaceuticals Inc (CPHRF) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...March 13, 2026 | finance.yahoo.comCipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)January 28, 2026 | finance.yahoo.comDiscovering Canada's Undiscovered Gems In January 2026January 22, 2026 | finance.yahoo.comCipher Pharmaceuticals Has PotentialNovember 23, 2025 | seekingalpha.comSee More Headlines CPHRF Stock Analysis - Frequently Asked Questions How have CPHRF shares performed this year? Cipher Pharmaceuticals' stock was trading at $10.98 at the beginning of the year. Since then, CPHRF shares have increased by 6.4% and is now trading at $11.68. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) released its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The business had revenue of $9.10 million for the quarter, compared to analyst estimates of $10.87 million. How do I buy shares of Cipher Pharmaceuticals? Shares of CPHRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/05/2016Today7/22/2026Next Earnings (Estimated)8/06/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CPHRF Previous SymbolNASDAQ:CPHR CIKN/A Webwww.cipherpharma.com Phone(905) 602-5840FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (OTCMKTS:CPHRF) was last updated on 7/22/2026 by MarketBeat.com Staff. From Our PartnersAmerica’s answer to universal basic incomeRobert Kiyosaki, author of Rich Dad Poor Dad, is highlighting an income strategy he calls the Patriot Income P...Freedom Financial | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredTSM just handed Trump's secretive AI project $100 billionTaiwan Semiconductor just committed another $100 billion to U.S. chip manufacturing - on top of $165 billion a...InvestorPlace | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredElon is about to dominate the biggest arms race in tech historyMicrosoft, Amazon, Alphabet, and Meta have collectively poured nearly $700 billion into AI infrastructure in 2...The Oxford Club | SponsoredIt all happens tonight.Tonight, trader Sean Allison is hosting a live session to walk through his Zero-Dollar Trade Advantage strateg...Trade Thirsty | SponsoredThe options guide that actually starts at the beginningMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cipher Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
